Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
Retrieved on:
Tuesday, October 19, 2021
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Nursing, MD, COVID-19, Patient, Mayo Clinic, Nasdaq, CRP, LB, American College, Physician, Principal, Pharmaceutical industry, use of CRP to identify immune phenotypes in hospitalized COVID-19 patients, Humanigen, USE OF CRP TO IDENTIFY IMMUNE PHENOTYPES IN HOSPITALIZED COVID-19 PATIENTS, HUMANIGEN
In our LIVE-AIR trial, 78% of the LIVE-AIR study population had a baseline CRP less than 150mg/L, representing a substantial population.
Key Points:
- In our LIVE-AIR trial, 78% of the LIVE-AIR study population had a baseline CRP less than 150mg/L, representing a substantial population.
- To test this hypothesis, these UK-based researchers conducted a retrospective longitudinal cohort study of 269 consecutive patients admitted to study hospitals in March 2020.
- The LIVE-AIR study achieved its primary endpoint of survival without ventilation measured through day 28 following treatment (HR: 1.54; 95%CI: 1.02-2.32, p=0.0403).
- C-reactive protein as a biomarker for improved efficacy of LENZILUMAB in patients with COVID-19: Results from the live-air trial.